Status:
UNKNOWN
Evaluating the Pharmacokinetics and Patient Outcomes of Buprenorphine Microdosing
Lead Sponsor:
United Health Services Hospitals, Inc.
Collaborating Sponsors:
Binghamton University
Conditions:
Opioid Use Disorder
Opioid Withdrawal
Eligibility:
All Genders
18+ years
Brief Summary
There are more than 2.1 million people in the United States with opioid use disorder, and according to preliminary data from the US Centers for Disease Control and Prevention opioid overdose deaths ro...
Eligibility Criteria
Inclusion
- Participants will include adults (at least 18 years of age) who have been enrolled and receiving consistent treatment in the methadone program for at least 6 months.
Exclusion
- Participants will be excluded if they are on a methadone dose \> 80 mg, have concurrent alcohol use or benzodiazepine use disorder, require opioids for a pain-related diagnosis, are a current suicide or homicide risk, have a current psychotic disorder (DSM-V) or untreated major depression, have a life-threatening or unstable medical problem, or are pregnant.
Key Trial Info
Start Date :
July 1 2022
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
December 31 2024
Estimated Enrollment :
20 Patients enrolled
Trial Details
Trial ID
NCT05307458
Start Date
July 1 2022
End Date
December 31 2024
Last Update
May 26 2023
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
UHS Addiction Medicine
Binghamton, New York, United States, 13903